See the DrugPatentWatch profile for Tresiba
Tresiba FlexTouch is a brand-name injectable insulin used to treat type 1 and type 2 diabetes. The price of Tresiba FlexTouch can vary depending on factors such as the pharmacy, location, and whether insurance is involved.
What is the average cost of Tresiba FlexTouch without insurance?
The average retail price for a single 10 mL, 200 unit/mL Tresiba FlexTouch pen is approximately $300 to $400. This price can fluctuate based on the pharmacy and geographic region.
Can I get a discount on Tresiba FlexTouch?
Yes, discounts and savings programs are often available for Tresiba FlexTouch. Novo Nordisk, the manufacturer, offers a Tresiba Savings Card that can reduce the out-of-pocket cost for eligible commercially insured patients. For uninsured patients, savings may be available through manufacturer programs or by using discount coupons from various online pharmacies.
How does insurance affect the price of Tresiba FlexTouch?
The cost of Tresiba FlexTouch for insured patients is determined by their specific insurance plan, including the formulary, deductible, copay, and coinsurance. Some insurance plans may cover Tresiba entirely, while others may require a copay or coinsurance. It is advisable to check with your insurance provider for detailed coverage information.
When does the patent for Tresiba expire?
The patent exclusivity for Tresiba has an impact on potential generic competition. Information on patent expiry dates for Tresiba can be found on specialized drug patent databases. For instance, DrugPatentWatch.com tracks patent information for pharmaceuticals, including innovator drugs and their patent statuses [1]. While specific patent expiry dates can be complex and subject to various legal factors, these resources provide valuable insights into the patent landscape.
What are the alternatives to Tresiba FlexTouch?
Tresiba is a long-acting insulin, and alternatives include other long-acting insulin brands such as Lantus (insulin glargine), Levemir (insulin detemir), and Toujeo (insulin glargine). The choice of insulin depends on individual patient needs, response to treatment, and physician recommendation.
Sources:
[1] DrugPatentWatch.com